The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Does dual agonism explain the effect size, or is it dose?

This is a generated summary. It shows the 9 most-liked posts from a topic of 69, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
CG
c.grimaldiTL224 May 2026#1

Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below.

A question about dual agonism that I think has a definite answer, unlike most of what I ask here.

I have the reasoning below and I am fairly confident about the direction. I am not confident about the size, and the size is what the decision turns on.

26 likes 2mo
TY
two_year_lineTL3Regular27 May 2026#4

Narrowing the opening post, because the general version has more than one answer.

The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather than a symptom scale, which is why that trial carries more weight than its size suggests. Two parallel trials with and without positive airway pressure addressed the obvious confounder directly.

I am confident about the direction and much less about the magnitude.

28 likes 2mo
JP
j.petrovTL2 Solution31 May 2026#9
s.ostergaard, post #5: Checked the dual agonism claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope. Go to post

On the mechanism question specifically: the honest position is that GIP agonism plausibly contributes and that the trial design cannot separate its contribution from simply achieving greater receptor engagement overall.

27 likes in reply to #5 2mo
RM
r.marsdenTL3Regular1 Jun 2026#11

The published pharmacokinetics show dose proportionality across the studied range, which means dose arithmetic behaves the way you would naively expect. That is not true of every compound and it is worth knowing which ones it is true of.

Worth one more sentence than it usually gets.

26 likes 2mo
AP
a.petrovTL26 Jun 2026#20

SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose response across three doses. The categorical thresholds (people reaching 10%, 15%, 20% loss) got the most attention but read less informatively than the mean weight change.

Not disagreeing with anyone above, just adding the bit I keep having to look up.

27 likes 2mo
CW
c.wijnbergTL2Member11 Jun 2026#28
sterile_table, post #15: Nothing to add on the substance. Thank you for taking the question at face value. Go to post

Adding the measurement that post #26 says would settle it.

SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose response across three doses. The categorical thresholds (people reaching 10%, 15%, 20% loss) got the most attention but read less informatively than the mean weight change.

That is all the detail I have. Someone else will have more.

29 likes in reply to #15 2mo
RM
r.mcalisterTL3Regular14 Jun 2026#36

Answering the dual agonism question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.

31 likes 1mo
PW
PharmNotes_WhitfieldTL4Pharmacist17 Jun 2026#42

Careful with the language on dual agonism. "Not detected" and "not present" are different findings and the first is a statement about the method.

26 likes 1mo
PM
physio_marchettiTL2Physiotherapist29 Jun 2026#68
PharmNotes_Whitfield, post #42: Careful with the language on dual agonism. "Not detected" and "not present" are different findings and the first is a statement about the method. Go to post

If someone has run dual agonism properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.

28 likes in reply to #42 29d

Read the full topic (69 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
The 2.5 mg starting dose is not a therapeutic dose — why that matters
The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…
BMRMAWSOML+119 136 5.6k 2mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
KHSCGIMYG+150 163 22k 11mo
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…
APPOELIGR+17 21 17k 12d
SURMOUNT-4 and what withdrawal data does and does not tell an individual
SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…
NSLMAADKA 4 42k 11mo
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest
Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
BAIDO 2 23k 21mo

Related topics — sharing the tags SURPASS programme, SURMOUNT programme, tirzepatide

TopicParticipantsRepliesViewsActivity
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…
RIPREAGTMM+2 6 5.5k 7h
Journal club: the CagriSema phase 2 combination paper
On the subject in the title: Journal club: the CagriSema phase 2 combination paper Working notes rather than a conclusion. CagriSema phase 2 combination paper — I have the observation and I do not trust my…
PFKMM 2 329 21h
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
CRHKASMISC+14 18 15k 3mo
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…
DPSGRIEDMB+80 91 10k 11mo
Biased agonism: a real phenomenon, an over-used explanation — what changed since
Biased agonism: a real phenomenon, an over-used explanation — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Biased agonism is…
EKJHROKFEK+49 56 47k 17mo